Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2017 December;152(6) > Giornale Italiano di Dermatologia e Venereologia 2017 December;152(6):597-606

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

A Journal on Dermatology and Sexually Transmitted Diseases


Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,311


eTOC

 

REVIEW  


Giornale Italiano di Dermatologia e Venereologia 2017 December;152(6):597-606

DOI: 10.23736/S0392-0488.17.05737-6

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Phototherapy of mycosis fungoides

Franz TRAUTINGER 1, 2

1 Department of Dermatology and Venereology, University Hospital of St. Pölten, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria; 2 Karl Landsteiner Institute of Dermatological Research, St. Pölten, Austria


PDF  


Mycosis fungoides (MF), the most common variant among cutaneous T cell lymphomas (CTCL), is characterized in its early stages by clonal proliferation of malignant T-cells in the skin manifesting as erythematous patches and plaques with a chronic course and progression to cutaneous tumors and extracutaneous organs in some patients. Skin directed therapies (SDT) are primarily used for effective palliation in early stage disease. Phototherapy with ultraviolet A radiation combined with 8-methoxypsoralen (PUVA) and with ultraviolet B radiation (UVB) has a longstanding history in the treatment of MF and are highly effective in inducing remissions. Patients with erythroderma and blood involvement benefit from treatment with extracorporeal photochemotherapy (ECP) where peripheral blood is exposed to PUVA. Phototherapy can be safely combined with systemic agents, most notably interferon-alpha and retinoids. Recently updated treatment guidelines have been published to provide evidence based algorithms for the stage-oriented treatment of MF. PUVA and narrow-band UVB (NB-UVB) are recommended as first line treatment for early stages with combination modalities reserved for refractory and more advanced cases and ECP is among the standard treatments for MF erythroderma. Areas of uncertainty relate to optimized treatment dose and schedules, the use of phototherapy for maintenance, and the role of newer phototherapeutic modalities (e.g. ultraviolet A1 radiation, excimer sources, photodynamic therapy) in the treatment of MF.


KEY WORDS: Lymphoma, T-cell, cutaneous - Mycosis fungoides - PUVA therapy

top of page

Publication History

Issue published online: October 18, 2017
Article first published online: July 28, 2017
Manuscript accepted: July 28, 2017
Manuscript received: July 23, 2017

Cite this article as

Trautinger F. Phototherapy of mycosis fungoides. G Ital Dermatol Venereol 2017;152:597-606. DOI: 10.23736/S0392-0488.17.05737-6

Corresponding author e-mail

franz.trautinger@kl.ac.at